<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852407</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-TC14</org_study_id>
    <secondary_id>2017-000824-91</secondary_id>
    <nct_id>NCT03852407</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Cell Transplantation HLA-matched Donor After Flu-Mel vs Flu-Mel-ATG Conditioning</brief_title>
  <acronym>HLA</acronym>
  <official_title>Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Fludarabine-Melphalan Versus Fludarabine-Melphalan-ATG Reduced-intensity Conditioning: a Phase III Randomized Study From the Belgian Hematology Society (BHS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgian Hematological Society Transplant Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims at comparing two conditioning regimens (Fludarabine-Melphalan (FM)
      vs Fludarabine-Melphalan-ATG (FM-ATG)). The hypothesis is that the FM-ATG regimen will be
      associated to better cGRFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, open-label, phase III study, comparing 2
      conditioning regimens. A total of 284 eligible patients with HLA (Human Leukocyte
      Antigen)-matched donors will be randomized 1/1 between the FM arm and the FM-ATG arm, with
      stratification for donor type (related or unrelated). The recruitment period is 5 years with
      a 5-year follow-up plus a 10-year additional long-term follow-up (for Graft-versus-host
      disease (GVHD) status, disease status, second malignancy and QOL). The whole study will be
      completed within 20 years. The hypothesis is that the FM-ATG regimen will be associated to
      better cGRFS (current GVHD-free, relapse-free survival).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Severe different but expected complications
  </why_stopped>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2038</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2033</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Current GVHD-free, relapse-free survival (cGRFS)</measure>
    <time_frame>15 years (the primary endpoint will be first assessed after 191 events have been reached)</time_frame>
    <description>To compare the current GVHD-free, relapse-free survival (cGRFS) for patients in the 2 arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cGRFS according donor</measure>
    <time_frame>15 years</time_frame>
    <description>To compare cGRFS for patients conditioned with FM or FM-ATG separately in those transplanted with a related or an unrelated donor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse/progression rate</measure>
    <time_frame>15 years</time_frame>
    <description>To compare the relapse/progression rate for patients conditioned with FM or FM-ATG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate aGVHD</measure>
    <time_frame>6 months</time_frame>
    <description>To compare rate of grade II-IV and III-IV acute GVHD (Graft-versus-host disease) in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate cGVHD</measure>
    <time_frame>24 months</time_frame>
    <description>To compare rate of grade of moderate-severe chronic GVHD in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nonrelapse Mortality (NRM)</measure>
    <time_frame>15 years</time_frame>
    <description>To compare rate of Nonrelapse Mortality in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Leukemia Free Survival (LFS)</measure>
    <time_frame>15 years</time_frame>
    <description>To compare rate of Leukemia Free Survival in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>To compare rate of Overall Survival in patients conditioned with FM or FM-ATG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>15 years</time_frame>
    <description>To compare the proportion of patients alive without active disease and without systemic immunosuppression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hematopoietic engraftment</measure>
    <time_frame>2 years</time_frame>
    <description>To compare hematopoietic (whole blood and T cell chimerism) engraftment in the 2 arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the quality of immunologic reconstitution in the 2 arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Timing of immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the timing (days) of immunologic reconstitution in the 2 arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of bacterial infections</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the incidences of bacterial infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of fungal infections</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the incidences of fungal infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of viral infections</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the incidences of viral infections (number of episode, site, grade) in the 2 arms, in the whole group of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess Thymoglobulin (ATG) Pharmacokinetic</measure>
    <time_frame>10 days</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with cGRFS</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with cGRFS</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with NRM</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with NRM</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with OS</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with OS</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with Relapse/progression</measure>
    <time_frame>15 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with Relapse/progression</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with Infections</measure>
    <time_frame>1 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with Infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG Pharmacokinetic in association with immunologic reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>To assess kinetics of functional ATG serum levels (mg/L) in the FM-ATG arm in association with immunologic reconstitution (CD4 and NAIVE T cells counts)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myeloid Leukemia in Remission</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Acute Lymphoid Leukemia in Remission</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphoid Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludarabine-Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It consists in IV fludarabine 30 mg/m2 on days -5, -4, -3, -2 and -1 (total dose 150 mg/m2; 80% of the dose if creatinine clearance between 30% and 70% and 60% of the dose if clearance &lt; 30%.) and melphalan given at the dose of 140 mg/m2 on day -2 (Adjusted body weight should be use in case of patient body weight &gt; 120% ideal body weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It consists in IV fludarabine 30 mg/m2 on days -5, -4, -3, -2 and -1 (total dose 150 mg/m2; 80% of the dose if creatinine clearance between 30% and 70% and 60% of the dose if clearance &lt; 30%.) and melphalan given at the dose of 140 mg/m2 on day -2 (Adjusted body weight should be use in case of patient body weight &gt; 120% ideal body weight) and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)</description>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140mg/m² on day -2</description>
    <arm_group_label>Fludarabine-Melphalan</arm_group_label>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m² on days -5,-4,-3,-2,-1.</description>
    <arm_group_label>Fludarabine-Melphalan</arm_group_label>
    <arm_group_label>Fludarabine-Melphalan-thymoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients

          -  Diseases: Hematological malignancies confirmed histologically:

               -  Acute Myeloid Leukemia (AML) in morphological Complete Remission (CR) or not in
                  morphological CR but not rapidly progressing (i.e. no need to give medications
                  such as hydroxyurea to maintain White Blood Cell (WBC) count &lt; 10 000 x109/mL);

               -  Myelodysplastic syndromes (MDS);

               -  Chronic myeloid leukemia (CML) in Chronic or Accelerated Phase;

               -  Myeloproliferative Syndrome (MPS) not in blast crisis,

               -  MDS/MPS overlap,

               -  Acute Lymphoid Leukemia (ALL) in CR;

               -  Multiple myeloma;

               -  Chronic Lymphoid Leukemia (CLL);

               -  Non-Hodgkin's lymphoma (NHL aggressive should have chemosensitive disease);

               -  Hodgkin's disease with chemosensitive disease.

          -  Clinical situations

               -  Theoretical indication for a standard allo-transplant, but not feasible because:

                    -  Age &gt; 50 yrs;

                    -  Unacceptable end organ performance;

                    -  The physician's decision;

                    -  The patient's decision

               -  Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is
                  preferred (eg CLL, MCL)

          -  Other inclusion criteria

               -  Male or female; fertile patients must use a reliable contraception method;

               -  Age 18-75 yrs (children of any age are not allowed in the protocol);

               -  Informed consent given by patient or his/her guardian if indicated.

        Donors

          -  Male or female;

          -  Any age;

          -  Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C,
             -DRB1, and -DQB1) HLA allele matched unrelated donor;

          -  Weight &gt; 15 Kg (because of leukapheresis);

          -  Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according
             to standard procedures;

          -  Informed consent given by donor or his/her guardian if indicated, as per donor center
             standard procedures.

        Exclusion Criteria:

        Patients

          -  Any condition not fulfilling inclusion criteria;

          -  Human Immunodeficiency Virus positive;

          -  Non-hematological malignancy(ies) (except non-melanoma skin cancer) active &lt; 3 years
             before Hematopoietic Cell Transplantation (HCT).

          -  Life expectancy severely limited by disease other than malignancy;

          -  Central Nervous System involvement with disease refractory to intrathecal
             chemotherapy.

          -  Terminal organ failure, except for renal failure (dialysis acceptable)

               1. Cardiac: Symptomatic coronary artery disease; ejection fraction &lt;40%;
                  uncontrolled arrhythmia, uncontrolled hypertension;

               2. Pulmonary: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)&lt; 40% and/or
                  receiving supplementary continuous oxygen, Forced Expiratory Volume in 1 Second
                  (FEV1)&lt; 40%;

               3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal
                  hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding
                  esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic
                  dysfunction evinced by prolongation of the prothrombin time, ascites related to
                  portal hypertension, bacterial or fungal liver abscess, biliary obstruction,
                  chronic viral hepatitis with total serum bilirubin &gt;3 mg/dL, and symptomatic
                  biliary disease;

          -  Uncontrolled infection;

          -  Karnofsky Performance Score &lt;70%;

          -  Patient is a fertile man or woman who is unwilling to use contraceptive techniques
             during and for 12 months following treatment;

          -  Patient is a female who is pregnant or breastfeeding;

          -  Any condition precluding the use of melphalan or Thymoglobulin;

        Donors

          -  Any condition not fulfilling inclusion criteria;

          -  Unable to undergo leukapheresis because of poor vein access or other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Baron, MD,Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Liège</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJ Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta Roeselare</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Frédéric Baron</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hematological malignancies</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Progression free survival</keyword>
  <keyword>Allogeneic hematopoeitic cell transplantation</keyword>
  <keyword>HLA-matched donor</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>Overall survival</keyword>
  <keyword>ATG PK</keyword>
  <keyword>Immunosuppressive regimen</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

